Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.55 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.55 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | MYC | P01106 | 1/20 | 0.34 |
| ▸ | WDR5 | P61964 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 6/20 | 0.34 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | NT5E | P21589 | 1/20 | 0.32 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL28327830 | 0.98 | ADORA3 (0.53) | ADORA3SLC6A3NOS1ALDH1A1HPGD | |
| SCHEMBL1241096 | 0.80 | ADORA3 (0.56) | ADORA3SLC6A3NOS1ALDH1A1HPGD | |
| SCHEMBL1062364 | 0.78 | ADORA3 (0.55) | ADORA3SLC6A3NOS1ALDH1A1HPGD | |
| SCHEMBL28327828 | 0.78 | ADORA3 (0.55) | ADORA3SLC6A3NOS1ALDH1A1HPGD | |
| SCHEMBL1063493 | 0.78 | ADORA3 (0.50) | ADORA3SLC6A3NOS1ALDH1A1HPGD | |
| SCHEMBL1348269 | 0.76 | KDM4E (0.32) | ADORA3SLC6A3KDM4ELOXL2 | |
| SCHEMBL27874802 | 0.75 | LOXL2 (0.33) | ADORA3SLC6A3KDM4ESMN1; SMN2LOXL2 | |
| SCHEMBL2823118 | 0.74 | LMNA (0.39) | ADORA3SLC6A3ALDH1A1KDM4ESMN1; SMN2 | |
| SCHEMBL15865702 | 0.74 | HCAR2 (0.45) | ADORA3SLC6A3KDM4ELOXL2 | |
| Hydrochloric Acid SCHEMBL28145192 | 0.72 | HCAR2 (0.44) | ADORA3SLC6A3KDM4ELOXL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2024-07-16 | — | — | US | disclosed |
| US-11077095-B2 | Methods for treating neurodegenerative disorders | ALZHEON, INC. (US) | 2021-08-03 | — | — | US | disclosed |
| EP-2569375-B1 | MODIFIED PIGMENTS | CABOT CORP (US) | 2017-11-22 | — | — | EP | disclosed |
| US-8771411-B2 | Modified pigments | CABOT CORPORATION (US) | 2014-07-08 | — | — | US | disclosed |
| WO-2011143533-A2 | MODIFIED PIGMENTS | CABOT CORPORATION (US) | 2011-11-17 | — | — | WO | disclosed |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2010-10-07 | — | — | US | disclosed |
| WO-2009140309-A2 | BORON-CONTAINING SMALL MOLECULES | ANACOR PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| US-7361659-B2 | Pyrrazolo-pyrimidine derivatives | HOFFMANN-LA ROCHE INC. (US) | 2008-04-22 | — | — | US | disclosed |
| EP-1851225-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2007-11-07 | — | — | EP | disclosed |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | US | disclosed |
| WO-2006084634-A1 | PYRAZOLO-PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS | F.HOFFMANN-LA ROCHE AG (CH) | 2006-08-17 | — | — | WO | disclosed |
| CN-1636563-A | Thiazole derivatives | AVON PROD INC (US) | 2005-07-13 | — | — | CN | disclosed |
| US-20050137239-A1 | Thiazole derivatives | AVON PRODUCTS, INC. | 2005-06-23 | — | — | US | disclosed |
| EP-1543824-A2 | Thiazole derivatives to counter advanced glycation | Avon Products, Inc. (US) | 2005-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11077095-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | ADORA3 3038/4885SLC6A3 572/4885NOS1 2640/4885 |
| US-20050137239-A1 | Thiazole derivatives | TYR, AGER, AOX1 | ADORA3 3555/4885SLC6A3 4167/4885NOS1 825/4885 |
| US-12036208-B2 | Methods for treating neurodegenerative disorders | NLN, CLN6, SNCA | ADORA3 3038/4885SLC6A3 572/4885NOS1 2640/4885 |
| US-20060183756-A1 | Pyrrazolo-pyrimidine derivatives | GRM1, GRM2, GRM3 | ADORA3 61/4885SLC6A3 1417/4885NOS1 3387/4885 |
| US-20100256092-A1 | BORON-CONTAINING SMALL MOLECULES | BCL6B, BCL6, BTD | ADORA3 3501/4885SLC6A3 1290/4885NOS1 4487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.